Euroopa Liit -
eesti -
EMA (European Medicines Agency)
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastilised ained - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
Eesti -
eesti -
Ravimiamet
walpoles buffer intravesikaallahus
arnolds veterinary products limited - jää-äädikhape+naatriumatsetaattrihüdraat - intravesikaallahus - 25ml 1tk
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
fampridine accord
accord healthcare s.l.u. - fampridine - hulgiskleroos - muud närvisüsteemi ravimid - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
raptiva
serono europe limited - efalizumab - psoriaas - immunosupressandid - mõõduka kuni raske kroonilise naastulise psoriaasiga täiskasvanud patsientidele, kes ei reageerinud, või esineb vastunäidustusi või esineb muu süsteemse raviga, sh tsüklosporiini, metotreksaati või puva-ravi (vt lõik 5. 1 - kliiniline efektiivsus).
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
udenyca
era consulting gmbh - pegfilgrastim - neutropeenia - immunostimulants, , mesilaspere stimuleerivaid faktoreid - neutropeenia ja febriilse neutropeenia esinemissageduse vähendamine ravitud tsütotoksilise kemoteraapia pahaloomulise kasvaja (välja arvatud krooniline müeloidne leukeemia ja müelodüsplastilised sündroomid).
Eesti -
eesti -
Ravimiamet
iohexol imax süstelahus
imax diagnostic imaging limited - joheksool - süstelahus - 647mg 1ml 200ml 10tk; 647mg 1ml 100ml 10tk; 647mg 1ml 50ml 10tk; 647mg 1ml 500ml 10tk; 647mg 1ml 500ml 5tk
Eesti -
eesti -
Ravimiamet
iohexol imax süstelahus
imax diagnostic imaging limited - joheksool - süstelahus - 755mg 1ml 500ml 5tk; 755mg 1ml 100ml 10tk; 755mg 1ml 50ml 10tk; 755mg 1ml 500ml 10tk; 755mg 1ml 200ml 10tk